← Back to Patent Explorer
US4237044A Expired / Lapsed US ⏱️ 0.0 years remaining

Antibodies against creatinekinase-M8 and process for the production thereof

Assignee: Merck Patent GmbH
•
Filing: 1979-05-08
•
Granted: 1980-12-02
•
Expires: 1999-05-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Antibodies against the M subunit of CK isoenzymes having a molecular weight between about 130,000 and 210,000, and inhibiting the enzymatic activity of the M subunit, optionally also in the presence of CK substrates, without inactivating the enzymatic activity of the B subunit of any CK-MB which may be present, are described. A process for the production of these antibodies comprises inoculating animals with activated CK-MM and recovering the antibodies in a conventional manner.

Inventors

  • 👤 Uwe Wurzburg
  • 👤 Norbert Hennrich
  • 👤 Hans-Dieter Orth
  • 👤 Hermann Lang

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 08:17
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/70; C; C07; C07K; C07K16/00; C07K16/40; G01N33/53; G01N33/573; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S530/00; Y10S530/827; Y10S530/841

Claims Analysis

Total Claims: 20
Claim 1
Independent Claim 186 words
Antibodies having a molecular weight of 130,000-210,000 and a sedimentation constant between 6S and 8S; and being capable of effecting in creatinekinase-MM (CK-MM) and creatinekinase-MB (CK-MB) complete inhibition of enzymatic activity of the M subunit without inhibiting the enzymatic activity of the B subunit and without precipitation; wherein complete inhibition of the enzymatic activity of said M subunit of creatinekinase leaves less than 5 U./l. of said enzymatic activity intact, and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l., and wherein said antibodies are substantially free of creatinekinase-BB (CK-BB) isoenzyme activity; wherein said antibodies are prepared by the steps of activating a CK-MM antigen from skeletal muscle of humans, monkeys, pigs or cattle by an activator for --SH groups selected from the group consisting of N-acetylcysteine, mercaptoethanol, dithioerythritol, glutathione, cysteine, dithiothreitol, S-(2-aminoethyl)-isothiouronium bromide hydrobromide and thioglycolic acid or a divalent metal ion activator selected from the group consisting of magnesium, manganese, calcium and cobalt, or a mixture of activators; inoculating a goat with the thus-activated CK-MM antigen; withdrawing blood from the goat; and isolating said antibodies from the withdrawn blood.
Claim 2
Dependent Claim 186 words
Antibodies having a molecular weight of 130,000-210,000 and a sedimentation constant between 6S and 8S; and being capable of effecting in creatinekinase-MM (CK-MM) and creatinekinase-MB (CK-MB) complete inhibition of enzymatic activity of the M subunit without inhibiting the enzymatic activity of the B subunit and without precipitation; wherein complete inhibition of the enzymatic activity of said M subunit of creatinekinase leaves less than 5 U./l. of said enzymatic activity intact, and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l., and wherein said antibodies are substantially free of creatinekinase-BB (CK-BB) isoenzyme activity; wherein said antibodies are prepared by the steps of activating a CK-MM antigen from skeletal muscle of humans, monkeys, pigs or cattle by an activator for --SH groups selected from the group consisting of N-acetylcysteine, mercaptoethanol, dithioerythritol, glutathione, cysteine, dithiothreitol, S-(2-aminoethyl)-isothiouronium bromide hydrobromide and thioglycolic acid or a divalent metal ion activator selected from the group consisting of magnesium, manganese, calcium and cobalt, or a mixture of activators; inoculating a goat with the thus-activated CK-MM antigen; withdrawing blood from the goat; and isolating said antibodies from the withdrawn blood.
Claim 3
Dependent Claim 40 words
The antibodies of claim 1, which are able to effect complete inhibition of said enzymatic activity of said M subunit in CK-MM and CK-MB without inhibiting said enzymatic activity of said B subunit, even in the presence of CK substrate.
Claim 4
Dependent Claim 29 words
The antibodies of claim 1, wherein the CK-MM antigen is activated by dialysis against the activator in the presence of a dialysis buffer for 1-200 hours at 1°-30° C.
Claim 5
Dependent Claim 18 words
The antibodies of claim 1, wherein 10-500 mM of activator is used per mg. of creatinekinase-MM being activated.
Claim 6
Dependent Claim 11 words
The antibodies of claim 1, wherein the activator is magnesium ions.
Claim 7
Dependent Claim 13 words
The antibodies of claim 1, wherein the activator is N-acetylcysteine, mercaptoethanol or dithioerythritol.
Claim 8
Dependent Claim 16 words
The antibodies of claim 1, wherein the activator is magnesium ions and N-acetylcysteine, mercaptoethanol or dithioerythritol.
Claim 9
Dependent Claim 51 words
The antibodies of claim 7, wherein the CK-MM is activated by dialysis against the activator in the presence of a dialysis buffer for 1-200 hours at 1°-30° C.; 10-500 mM of activator is used per mg. of creatinekinase-MM being activated; and the activator is magnesium ions and N-acetylcysteine mercaptoethanol or dithioerythritol.
Claim 10
Dependent Claim 14 words
The antibodies of claim 8, wherein the CK-MM antigen is from human skeletal muscle.
Claim 11
Dependent Claim 58 words
The antibodies of claim 1, which have a molecular weight of 160,000-180,000 and a sedimentation constant of about 7S and wherein complete inhibition of the enzyme activity of said M subunit of creatinekinase leaves less than 3 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is less than 5 U./l.
Claim 12
Dependent Claim 11 words
The antibodies of claim 10, which are antihuman skeletal muscle CK-MM.
Claim 13
Dependent Claim 126 words
In the method for producing creatinekinase-MM (CK-MM) antibodies with a molecular weight of 130,000-210,000 and a sedimentation constant between 6S and 8S consisting of the steps of inoculating an animal with a CK-MM antigen; withdrawing blood from the animal; and isolating said antibodies from the withdrawn blood, the improvement which comprises activating the CK-MM antigen, just prior to inoculation, with an activator for --SH groups selected from the group consisting of N-acetylcysteine, mercaptoethanol, dithioerythritol, glutathione, cysteine, dithiothreitol, S-(2-aminoethyl)-isothiouronium bromide hydrobromide and thioglycolic acid or a divalent metal ion activator selected from the group consisting of magnesium, manganese, calcium and cobalt, or a mixture of activators; wherein the CK-MM antigen is from skeletal muscle of humans, monkeys, pigs, or cattle, and the inoculated animal is a goat.
Claim 14
Dependent Claim 126 words
In the method for producing creatinekinase-MM (CK-MM) antibodies with a molecular weight of 130,000-210,000 and a sedimentation constant between 6S and 8S consisting of the steps of inoculating an animal with a CK-MM antigen; withdrawing blood from the animal; and isolating said antibodies from the withdrawn blood, the improvement which comprises activating the CK-MM antigen, just prior to inoculation, with an activator for --SH groups selected from the group consisting of N-acetylcysteine, mercaptoethanol, dithioerythritol, glutathione, cysteine, dithiothreitol, S-(2-aminoethyl)-isothiouronium bromide hydrobromide and thioglycolic acid or a divalent metal ion activator selected from the group consisting of magnesium, manganese, calcium and cobalt, or a mixture of activators; wherein the CK-MM antigen is from skeletal muscle of humans, monkeys, pigs, or cattle, and the inoculated animal is a goat.
Claim 15
Dependent Claim 29 words
The method of claim 12, wherein the CK-MM antigen is activated by dialysis against the activator in the presence of a dialysis buffer for 1-200 hours at 1°-30° C.
Claim 16
Dependent Claim 18 words
The method of claim 12, wherein 10-500 mM of activator is used per mg. of creatinekinase-MM being activated.
Claim 17
Dependent Claim 11 words
The method of claim 12, wherein the activator is magnesium ions.
Claim 18
Dependent Claim 13 words
The method of claim 12, wherein the activator is N-acetylcysteine, mercaptoethanol or dithioerythritol.
Claim 19
Dependent Claim 16 words
The method of claim 12, wherein the activator is magnesium ions and N-acetylcysteine, mercaptoethanol or dithioerythritol.
Claim 20
Dependent Claim 52 words
The method of claim 12, wherein the CK-MM antigen is activated by dialysis against the activator in the presence of a dialysis buffer for 1-200 hours at 1°-30° C.; 10-500 mM of activator is used per mg. of creatinekinase-MM being activated; and the activator is magnesium ions and N-acetylcysteine, mercaptoethanol or dithioerythritol.

References Cited (Backward Citations)

US3932221A Cited
US4012285A Cited
US4067775A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-12-02 1984-06-02 1984-12-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-12-02 1988-06-02 1988-12-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-12-02 1992-06-02 1992-12-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag